Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort ascending
Aug
7
2020
DOJ Secures Admission of Guilt, Agrees to Deferred Prosecution Agreement for Generic Drug Manufacturer Accused of Price Fixing MoginRubin
Jun
17
2021
Fifth Circuit Upholds FTC Finding: Impax Lab's Reverse Payment Scheme Was Illegal MoginRubin
Oct
21
2021
$25 Billion Kroger/Albertsons Deal Fuels Antitrust Concerns MoginRubin
Mar
1
2021
“Big Poultry” Producer Pleads Guilty to Price Fixing MoginRubin
Apr
10
2023
Khan's FTC Reportedly Reviving Price Discrimination Law to Investigate What Big Retailers Pay for Cola MoginRubin
Apr
14
2023
FTC Files Brief in Support of Private Antitrust Case Against Makers of Parkinson’s Drug MoginRubin
Oct
17
2019
California Tackles Big Pharma’s Anticompetitive ‘Pay for Delay’ Practices That Slow Down Lower-Cost Generic Drug Development MoginRubin
Mar
24
2023
Pfizer Expands Cancer Drug Portfolio with $43 Billion Biotech Acquisition MoginRubin
Mar
24
2023
Judge Approves $25M Settlement of Antitrust Action Against J&J for Allegedly Blocking Biosimilars MoginRubin
Mar
24
2020
Enforcers, Experts Discuss Tamping Down Anticompetitive Behavior in Bio Market During FDA/FTC Workshop MoginRubin
Oct
24
2019
Beef Buyer Class Action Says ‘Big Beef’ Colluded to Score Record Profits by Manipulating Capacity MoginRubin
Jan
11
2022
7th Circuit: Is Each Transmission of Biometric Data a BIPA Violation? MoginRubin
Apr
14
2022
Full Ninth Circuit Removes Unwarranted Hurdles to Class Certification in Big Tuna Antitrust Case MoginRubin
Dec
18
2019
FTC Challenges Illumina-PacBio Merger over for Next-Gen DNA Sequencing MoginRubin
Sep
18
2019
‘Big Tuna’ Antitrust Case Among Latest to Discuss Daubert Test at Class Certification Stage. But What’s Too Rigorous? MoginRubin
Feb
28
2020
FTC, FDA Team Up Against Anticompetitive Tactics in Biological Product Industry MoginRubin
Oct
29
2020
Pharma: Consumer Groups, States Support Reviving Generic Drugs Antitrust Case Against AbbVie MoginRubin
Oct
12
2021
California Cannabis Shop Wins 15M at Industry's First Antitrust Trial MoginRubin
Aug
3
2022
AbbVie's Humira Patent Settlement Not a Violation of Sherman Antitrust Act, Seventh Circuit Affirms MoginRubin
Sep
18
2019
Consumer Groups and Unions Tell FTC: AbbVie-Allergen Merger Will Deny Access to More Effective and Affordable Drugs MoginRubin
Oct
29
2020
Healthcare: Anticompetitive Tying Class Action Moves Forward Against Sutter Health MoginRubin
Feb
5
2020
Agencies’ Antitrust Suit Against Drug Maker Underscores Challenges of Bringing Biosimilars to Market MoginRubin
Jul
18
2021
President Biden’s Recent Executive Order on Promoting Competition in the American Economy Highlights the Healthcare Sector Nelson Mullins
Jan
5
2023
Biden Administration Publishes Unified Agenda, Revealing FDA’s Planned Regulatory Actions for 2023 Nelson Mullins
Feb
27
2023
Old North State Report – Feb. 27, 2023 Nelson Mullins
Mar
28
2023
FDA Revamps Guidance Concerning Use of Electronic Systems, Records, and Signatures in Clinical Investigations Nelson Mullins
Apr
7
2023
Potential Nitrosamine Contamination Results in Another Voluntary Pharmaceutical Recall Nelson Mullins
Oct
2
2023
FDA Proposes New Rule to Regulate Laboratory Developed Tests Nelson Mullins
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins